Chief Executive Officer

DSM finishes sale of pharma assets to US firm

DSM finishes sale of pharma assets to US firm

By Hank Schultz

DSM has completed a major milestone in its restructuring into a smaller, more profitable and more focused company as it finalized the sale of its pharmaceutical manufacturing assets to US-based Thermo Fisher Scientific Inc.

The company would like to intensify growth in Europe and Asia, it said.

Barentz reveals expansion plans after gaining added funds

By Joyeeta Basu

On the back of a deal with a ‘strong’ equity partner, Barentz International will use the additional funds to accelerate growth in its key markets in Europe, India, China and Asia Pacific, it said.

China’s krill market opening up to newcomers

China’s krill market opening up to newcomers

By RJ Whitehead

Canadian biotechnology company Neptune has followed its krill supply rivals Aker Biomarine in receiving New Food Raw Material certification in China, which allows the companies to sell their krill oil nutraceutical products in the county.

Norwegian company investigates ways to overcome vitamin K2 stability issues

Kappa Bioscience announces vitamin K2 stability project

By Annie-Rose Harrison-Dunn

Norwegian firm Kappa Bioscience has announced a research project into possible solutions to stability issues concerning vitamin K2, results of which could help manufacturers secure label claims.

Healthy food enzymes help Novozymes report 2012 growth

Healthy food enzymes help Novozymes report 2012 growth

By Nathan Gray

Increasing demand for industry to produce healthier foods helped Novozymes to a strong 2012 performance in its food and drink business, however the Danish enzyme specialist says growth was ‘below expectation’.

Groupe Caravelle to acquire equity stake in Naturex

Groupe Caravelle to acquire equity stake in Naturex

By Caroline Scott-Thomas

French industrial business Groupe Caravelle has said it intends to acquire an equity stake in Naturex, following Spanish group Natraceutical’s sale of its 15.35% stake in the company earlier this month.

Naturex reports H1 growth on back of acquisitions

Naturex reports H1 growth on back of acquisitions

By Nathan Gray

Natural ingredients supplier Naturex has reported a healthy 15% growth in sales for the first half of its financial year on the back of ‘positive contributions’ from the firm’s new acquisitions.

Sales jumped 37% to €272.2m for Raisio in H1

Raisio H1 EBIT jumps 73%

By Shane Starling

Finnish supplier Raisio has turned in a bumper half-year with earnings before interest, tax and depreciation (EBIT) surging from €10.3m to €16.2m – a 73% rise.

Danisco buy-out fails to dent DuPont Q2 earnings

Danisco buy-out fails to dent DuPont Q2 earnings

By Shane Starling

Dupont, which earlier in the year warned that its May $6.49bn acquisition of Danisco would dent its yearly profits, has defied expectations in second quarter results published today.

Naturex set for “one or two” acquisitions in 2011: President

Naturex set for “one or two” acquisitions in 2011: President

By Shane Starling

Naturex will expand again in 2011 with several “€5-20m” targets, 1.5 years after completing the €110m integration of Spanish supplier Natraceutical that made the French botanical extracts supplier the biggest in the world.

Naturex president: acquisition policy remains unchanged

Exclusive interview

Naturex president: acquisition policy remains unchanged

By Shane Starling

Naturex president and chief executive officer, Jacques Dikansky, tells Shane Starling why in August the French botanicals giant bought Spanish supplier, Natraceutical Group, to double its size for the third time since 2002.

Provexis enjoys fruits of health claims victory

Dispatches from FIE

Provexis enjoys fruits of health claims victory

Provexis chief executive officer, Stephen Moon tells Shane Starling why becoming the first company to achieve an article 13.5 proprietary health claim has been such a boon to his company.

Hoodia finds life after Unilever

Hoodia finds life after Unilever

By Shane Starling

Phytopharm, the UK start-up Unilever dumped in November after spending more than €20m euros in a failed attempt to develop a hoodia-based weight management product, says it is in discussions with major food and food supplements players about the South...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All